Franklin Biotechnology Discovery Fund Manager Performance Evaluation
| FRBRX Fund | USD 141.38 6.06 4.11% |
The fund shows a Beta (market volatility) of 1.06, which means a somewhat significant risk relative to the market. Franklin Biotechnology returns are very sensitive to returns on the market. As the market goes up or down, Franklin Biotechnology is expected to follow.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Franklin Biotechnology Discovery has generated negative risk-adjusted returns adding no value to fund investors. In spite of weak performance in the last few months, the Fund's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the fund investors.
...more1 | Franklin Biotechnology Discovery Fund Q3 2024 Commentary - Seeking Alpha | 11/20/2024 |
| Expense Ratio | 0.6900 |
Franklin |
Franklin Biotechnology Relative Risk vs. Return Landscape
If you would invest 16,182 in Franklin Biotechnology Discovery on September 20, 2024 and sell it today you would lose (2,044) from holding Franklin Biotechnology Discovery or give up 12.63% of portfolio value over 90 days. Franklin Biotechnology Discovery is currently producing negative expected returns and takes up 1.3742% volatility of returns over 90 trading days. Put another way, 12% of traded mutual funds are less volatile than Franklin, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Franklin Biotechnology Current Valuation
Fairly Valued
Today
Please note that Franklin Biotechnology's price fluctuation is very steady at this time. At this time, the entity appears to be fairly valued. Franklin Biotechnology shows a prevailing Real Value of $144.08 per share. The current price of the fund is $141.38. We determine the value of Franklin Biotechnology from reviewing fund fundamentals and technical indicators as well as its Probability Of Bankruptcy. In general, we advise acquiring undervalued mutual funds and dropping overvalued mutual funds since, at some point, mutual fund prices and their ongoing real values will submerge.
Since Franklin Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Franklin Mutual Fund. However, Franklin Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 141.38 | Real 144.08 | Hype 141.63 |
The intrinsic value of Franklin Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Franklin Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Franklin Biotechnology Discovery helps investors to forecast how Franklin mutual fund's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Franklin Biotechnology more accurately as focusing exclusively on Franklin Biotechnology's fundamentals will not take into account other important factors: Franklin Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Franklin Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of mutual funds, such as Franklin Biotechnology Discovery, and traders can use it to determine the average amount a Franklin Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.149
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FRBRX |
Estimated Market Risk
| 1.37 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Franklin Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Franklin Biotechnology by adding Franklin Biotechnology to a well-diversified portfolio.
Franklin Biotechnology Fundamentals Growth
Franklin Mutual Fund prices reflect investors' perceptions of the future prospects and financial health of Franklin Biotechnology, and Franklin Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Franklin Mutual Fund performance.
| Price To Earning | 19.51 X | ||||
| Price To Book | 4.46 X | ||||
| Price To Sales | 6.21 X | ||||
| Total Asset | 833.93 M | ||||
About Franklin Biotechnology Performance
Evaluating Franklin Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Franklin Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Franklin Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Under normal market conditions, the fund invests at least 80 percent of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20 percent of its net assets in equity or debt securities of any type of issuer. It is non-diversified.Things to note about Franklin Biotechnology performance evaluation
Checking the ongoing alerts about Franklin Biotechnology for important developments is a great way to find new opportunities for your next move. Mutual Fund alerts and notifications screener for Franklin Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Franklin Biotechnology generated a negative expected return over the last 90 days | |
| The fund retains 98.75% of its assets under management (AUM) in equities |
- Analyzing Franklin Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Franklin Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Franklin Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Franklin Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Franklin Biotechnology's management team can help you assess the Mutual Fund's leadership.
- Pay attention to analyst opinions and ratings of Franklin Biotechnology's mutual fund. These opinions can provide insight into Franklin Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| CEOs Directory Screen CEOs from public companies around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |